Clinical Guidelines

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

Share

Prostate cancer stands as the most frequently diagnosed cancer among men in Europe, highlighting the urgent need for enhanced biomarker testing and precision oncology. Ongoing advancements depend on multidisciplinary collaboration and patient engagement. With genetic insights illuminating treatment paths, including those impacted by homologous recombination repair changes, establishing testing protocols is vital. However, varying healthcare systems across Europe introduce challenges in biomarker accessibility, necessitating standardized yet locally adapted workflows to ensure timely and effective patient care.

Original Source(s)

From Tissue to Treatment

Optimizing biomarker testing in prostate cancer

  • by Lynda Corrigan, Stephen Finn

  • November 5, 2025

  • 7 min

Related Content

Breaking the Biomarker Bottlenecks: Part 2

Industry leaders from AstraZeneca, Leica Biosystems, and Danaher share their insights on AI’s power to democratize access to precision medicine

  • February 16, 2026

  • 9 min
Identifying HER2-low expression – A pathologist led slide review

Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression.

  • December 14, 2022

Democratizing Tumor Genomic Profiling With Tailored Content

Join Us With Agilent For Our Webinar On Democratizing Tumor Genomic Profiling. The webinar will discuss the range of available tumor genomic profiling assays (comprehensive, tumor-specific, customized) in the Agilent SureSelect Cancer product portfolio and much, much more!

  • June 26, 2024